Clinical Trial Search

Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants

Primary: Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis — 17.5; 27.8; 31.4 days — p=0.003

Primary: Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II — 31; 4; 45; 78 participants

Primary: Thrombosis — 8; 6 participants

Primary: Development of DVT (Deep Vein Thrombosis)

Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…

Primary: Number of Participants With Elevated Serum Activated Partial Thromboplastin Time Above the Normal Range (> 36.2 Seconds). — 1; 8 Participants

Primary: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds — 0.95; 1.10 ratio

Primary: Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. — 25; 31 Participants

Primary: Number of Participants With Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL) — 0; 12 Participants

Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants

Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…

Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…

Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1

Primary: The Primary Outcome Measure Was the Number of Participants With New Heparin Platelet Factor 4 (HIT Positive) Antibodies in Each Group Within 30 Days Following Surgery…

Primary: Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization — 87; 82 Percent AT-III activity (%) — p=0.092

Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…

Primary: Major Adverse Cardiac Events — 2 percentage of event

Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…

Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants

Primary: Number of Patients With Clinically Relevant Bleeding Events — 32; 32 Patients

Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants

Primary: Number or Participants With Antirecombinant Thrombin (rThrombin) Product Antibody at Baseline and Day 29 — 0; 0 Participants

Primary: Responder Patients — 72.2 percentage of subjects

Primary: The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to…

Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients

Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099

Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis

Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants

Primary: Lower Extremity Deep Vein Thrombosis — 4.8; 2.9 percentage of patients — p=0.025